Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101731 | 1.00 | GID4 (0.34) | GID4CYP19A1TBXAS1 | |
| SCHEMBL6101683 | 0.77 | GID4 (0.37) | GID4CYP19A1TBXAS1 | |
| SCHEMBL21350538 | 0.69 | GID4 (0.33) | GID4CYP19A1TBXAS1 | |
| SCHEMBL6098878 | 0.68 | KEAP1 (0.39) | GID4 | |
| SCHEMBL6101889 | 0.68 | KEAP1 (0.39) | GID4 | |
| SCHEMBL1265184 | 0.66 | CYP19A1 (0.42) | GID4CYP19A1TBXAS1 | |
| SCHEMBL14578643 | 0.66 | CYP19A1 (0.42) | GID4CYP19A1TBXAS1 | |
| SCHEMBL21350952 | 0.63 | — | — | |
| SCHEMBL13117920 | 0.63 | GID4 (0.37) | GID4CYP19A1TBXAS1 | |
| SCHEMBL8262015 | 0.63 | GID4 (0.37) | GID4CYP19A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041672-B2 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | GID4 356/4885CYP19A1 1319/4885TBXAS1 1048/4885 |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | HTR2C, HTR4, HTR5A | GID4 356/4885CYP19A1 1319/4885TBXAS1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.